wiki pageCreated: 2026-04-02T07:20:09By: crosslink-migrationQuality:
50%✓ SciDEXID: wiki-organizations-invicro
📖 Wiki Page
organization554 wordssynced 2026-04-02
Invicro
Type: Contract Research Organization (CRO)
Location: Boston, MA, USA (with global operations)
Founded: 2009 (spun out from Harvard Medical School imaging research)
Website: [invicro.com](https://www.invicro.com/)
Formerly: inviCRO (branding updated)
Type: Contract Research Organization (CRO)
Location: Boston, MA, USA (with global operations)
Founded: 2009 (spun out from Harvard Medical School imaging research)
Website: [invicro.com](https://www.invicro.com/)
Formerly: inviCRO (branding updated)
Overview
Mermaid diagram (expand to render)
Invicro is a specialty contract research organization (CRO) providing imaging core laboratory services, quantitative image analysis, and scientific consulting for clinical trials. Founded by researchers from Harvard Medical School's Center for Morphometric Analysis, Invicro has become a leading provider of neuroimaging core lab services for neurodegeneration trials, including multiple 4R tau PET imaging programs for PSP["@invicro2024"].
Invicro operates as a central imaging core for pharmaceutical companies and academic consortia, providing standardized image acquisition protocols, quality control, and centralized analysis across international multi-site trials. Their expertise in tau PET quantification has made them a key partner in PSP therapeutic development programs.
Services and Expertise
Imaging Core Laboratory Services
PET/MRI acquisition protocols: Standardized imaging protocols for multi-site trials
Quality control: Centralized image quality review and artifact detection
Tracer-specific quantification: Expertise in tau PET ligand analysis (flortaucipir, PI-2620, novel 4R tracers)
Longitudinal analysis: Tracking imaging biomarkers over time in clinical trials
Neuroscience Focus Areas
Invicro specializes in neuroimaging for:
Tauopathies: Alzheimer's disease, PSP, CBD, and other tauopathies
Invicro serves as the imaging core for the first-in-human study of novel 4R tau-selective PET radioligands (ABBV-964i and ABBV-965i) in PSP patients[@trial2024]. Their role includes:
Developing and validating standardized acquisition protocols for novel tracers
Cross-site harmonization of PET quantification
Central reading of imaging endpoints
Kinetic modeling analysis for new 4R-specific ligands
Tau PET Standardization for PSP
Invicro has contributed to standardization efforts for tau PET imaging in PSP:
Participating in multi-center phantom studies for PET scanner calibration
Developing region-of-interest templates specific to PSP subcortical structures
Establishing reference regions for specific binding quantification
Supporting regulatory submissions with imaging data packages
PROSPER Trial Support
While Ferrer leads the PROSPER Phase 2 trial of FNP-223 in PSP (NCT06355531), Invicro has provided imaging consultation for related tau biomarker studies, contributing to the development of OGA inhibitor imaging endpoints[@ferrer2025].
Key PSP Trial Partnerships
| Trial | Sponsor | Role | |-------|---------|------| | First-in-Human 4R Tau Ligand (NCT07348276) | Invicro (as sponsor) | Full imaging core lab | | PI-2620 Tau PET (NCT04715750) | Life Molecular Imaging | Quantitative analysis | | Biomarkers in Parkinsonian Syndromes (NCT06501469) | Academic consortium | Imaging consultation |
Corporate Structure
Invicro operates under the [IXICO Technologies](/companies/ixico-technologies) umbrella following acquisition, combining IXICO's digital biomarker expertise with Invicro's imaging core capabilities[@ixico2023]. This integration provides:
End-to-end imaging and digital biomarker services
Combined regulatory expertise across US and EU
Expanded site network for international trials
Cross-References
[Life Molecular Imaging](/companies/life-molecular-imaging) — Partner for PI-2620 PET tracer